4-(磺基氨基)苯甲酸 | 71195-74-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(磺基氨基)苯甲酸
• 英文名称: 4-sulfoamino-benzoic acid
• 英文别名: 4-Carboxy-phenylsulfamidsaeure；4-Sulfoamino-benzoesaeure；Benzoic acid, 4-(sulfoamino)-；4-(sulfoamino)benzoic acid
• CAS: 71195-74-9
• 化学式: C₇H₇NO₅S
• 分子量: 217.202
• InChiKey: HLIYJBPIVVVYRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  对硝基苯甲酸 在 水 、 sodium hydrogensulfite 作用下， 生成 4-(磺基氨基)苯甲酸
  参考文献：
  名称：

  Weil; Moser, Chemische Berichte, 1922, vol. 55, p. 736

  摘要：

  DOI：

文献信息

• Dispersants resistant to color change
  申请人：E.I. DU PONT DE NEMOURS AND COMPANY

  公开号：EP0323181A2

  公开（公告）日：1989-07-05

  Acrylic AB block copolymers that are useful as pigment dispersants and which are resistant to yellowing and other color changes, characterized by aromatic substituents bonded to the A segment of the block copolymer.

  丙烯酸 AB 嵌段共聚物，可用作颜料分散剂，具有耐黄变和其它颜色变化的特性，其特征是嵌段共聚物的 A 段上键有芳香族取代基。
• Modified gangliosides and the functional derivatives thereof
  申请人：FIDIA S.p.A.

  公开号：EP0433112A1

  公开（公告）日：1991-06-19

  N-acyl-N,N′-di-lysogangliosides, N′-acyl-N,N′-di-­lysogangliosides and N,N′-diacyl-N,N′-di-­lysogangliosides, in which the acyl groups are derived from an organic acid of the aliphatic, aromatic, araliphatic, alicyclic or heterocyclic series and in which at least one of the two acyl groups is not aliphatic, and their preparation are disclosed. Also disclosed is the preparation of the esters, inner esters, amides and hydroxy peracylates of these compounds and salts thereof. These compounds are useful in the treatment of pathologies of the central and peripheral nervous systems.

  N-acyl-N,N′-di-lysogangliosides, N′-acyl-N,N′-di-lysogangliosides和N,N′-diacyl-N,N′-di-lysogangliosides，其中酰基来自脂肪族、芳香族、脂环族、脂环族或杂环族的有机酸，并且其中至少有一个酰基不是脂肪族、本发明公开了两个酰基中至少有一个不是脂肪族的二乙酰基-N，N′-二赖糖糖苷及其制备方法。此外，还公开了这些化合物的酯、内酯、酰胺和羟基过酰基化合物及其盐的制备方法。这些化合物可用于治疗中枢和外周神经系统的疾病。
• Chemical sensing techniques employing liquid-core optical fibers
  申请人：World Precision Instruments, Inc.

  公开号：EP0909946A2

  公开（公告）日：1999-04-21

  A permeable optical fiber waveguide 10 with a liquid core 12 is employed as a probe for the detection or measurement of a chemical specie of interest by filling the waveguide core region with a light transmitting reagent liquid 12' which undergoes a change in an optical characteristic thereof when exposed to the chemical specie and then inserting the filled waveguide 10 into an environment in which the chemical specie may be present. The chemical specie, if present, will permeate through the waveguide wall and react with or be absorbed in the core liquid.

  带有液芯 12 的可渗透光纤波导 10 被用作探测或测量相关化学物质的探头，其方法是在波导芯区填充透光试剂液 12'，当接触到化学物质时，其光学特性会发生变化，然后将填充好的波导 10 插入可能存在化学物质的环境中。化学试剂（如果存在）将穿过波导壁，与核心液体发生反应或被核心液体吸收。
• [DE] LORAZEPAM UND DIPHENHYDRAMIN ENTHALTENDES SCHLAFMITTEL<br/>[EN] SOPORIFIC CONTAINING LORAZEPAM AND DIPHENHYDRAMINE<br/>[FR] SOMNIFERE CONTENANT DU LORAZEPAM ET DE LA DIPHENEHYDRAMINE
  申请人：MEDICHEMIE AG

  公开号：WO1998016231A1

  公开（公告）日：1998-04-23

  (DE) Gegenstand der Erfindung ist eine Mischung aus Lorazepam und Diphenhydramin oder eines Säureadditionssalzes von Diphenhydramin im Gewichtsverhältnis von 1:10 bis 1:50 zur Herstellung eines Schlafmittels, welches auch bei chronischer Einnahme keine negative Beeinträchtigung der cognitiven Leistungsfähigkeit zur Folge hat. Die cognitive Leistungsfähigkeit lässt sich bei längerer Einnahme des Kombinationspräparats sogar signifikant steigern. Das Präparat ist damit besonders geeignet für Patienten, welche unter chronischen Schlafstörungen leiden und bei denen eine weitere Beeinträchtigung ihrer bereits alters- oder krankheitsbedingt reduzierten cognitiven Leistungsfähigkeit nicht in Kauf genommen werden kann oder zu vermeiden ist.(EN) The invention relates to a mixture of lorazepam and diphenhydramine or an acid additive salt of diphenhydramine with a weight ratio from 1:10 to 1:50 for producing a soporific, which when chronically administered does not cause any negative impairment of the cognitive performance. Contrarily, cognitive performance can be significantly enhanced when the combined preparation is taken over a long period, thus making said preparation quite suitable for patients suffering from chronic sleep disorders, in whom further impairment of their already diminished cognitive performance due to age or disease is not tolerated or should be avoided.(FR) L'invention concerne un mélange de lorazépam et de diphènehydramine ou d'un sel d'addition d'acide de diphènehydramine dans un rapport en poids de 1:10 à 1:50 pour la production d'un somnifère qui, en cas d'absorption chronique, n'a aucun effet négatif sur les performances cognitives. En cas d'une prise de cette préparation à long terme, les performances cognitives peuvent même augmenter de façon significative. La préparation est donc particulièrement adaptée aux patients souffrant de troubles du sommeil chroniques, pour lesquels une autre influence néfaste sur les performances cognitives déjà réduites en raison de l'âge ou d'une maladie est inacceptable ou doit être évitée.

  basically, there are two substances involved here: lorazepam and diphenhydramine, or diphenhydramine in the form of an acid addition salt, with a weight ratio between 1:10 and 1:50. This mixture is used to create a sleep aid. The key feature of this product is that, even when taken chronically, it doesn’t negatively affect cognitive performance. However, if taken over a long period, cognitive performance can actually improve significantly. This makes the product especially suitable for patients with chronic insomnia (or those with sleep issues). For such individuals, further negatively affecting cognitive performance (due to age or pre-existing health conditions) is not permissible – or at least they should be avoided.
• Lorazepam-haltiges Schlafmittel
  申请人：MEDICHEMIE AG

  公开号：EP0151245B1

  公开（公告）日：1990-09-26